An AI foundation model capable of predicting gene activity across many different human cell types may expedite research for ...

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

“Bev has significant kyphoscoliosis (curvature of the spine that’s both sideways and forward/backward), which made the biopsy ...

OXcan was founded in 2020 by Dr. Peter Jianrui Liu and Dr. Andreas Halner to advance early cancer detection using liquid biopsy.

Researchers at Newcastle University in the UK have developed a groundbreaking tool called “DeepMerkel,” powered by artificial ...

A new study demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a ...

A new artificial intelligence tool combines data from medical images with text to predict cancer prognoses and treatment responses.

Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding ...

This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...

The melding of visual information (microscopic and X-ray images, CT and MRI scans, for example) with text (exam notes, communications between physicians of varying specialties) is a key component of ...

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial ...